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Deactivation to antineoplastic agents is becoming a stan-
dard of care in hemato-oncology. Hypersensitivity to anti-
neoplastic drugs represents an increasing problem in oncol-
ogy due to the use of an expanded repertoire of different 
agents. Additionally, since these (new) agents show a high-
er efficacy, patients are exposed to the same antineoplastic 
drug for a longer time period resulting in a higher chance 
of sensitization. Once sensitization to a certain antineoplas-
tic drug is present, therapy has to be modified, irrespec-
tive of its efficacy. Treatment modifications avoiding drugs 
causing hypersensitivity may affect the course of the disease 
and life expectancy. Therefore, therapeutic interventions are 
needed to allow the continuation of efficient antineoplastic 
drugs even if a hypersensitivity reaction has occurred.
As an example, hypersensitivity reactions to carboplatin 
and oxaliplatin occur frequently. Both these drugs are 
commonly used as part of poly-chemotherapy–regimens. 
Incidences of 12% to 17% of hypersensitivity reactions 
have been reported for these treatment modalities in the 
literature. More than 50% of the reported reactions were 
classified as moderate to severe [1-3].
To illustrate the typical clinical situation we should like 
to present the following case. A 42 year old male patient 
was diagnosed with borderline resectable adenocarcinoma 
of the pancreatic head. Surgical exploration was performed 
at another hospital, but resection was not attempted due 
to unexpectedly extensive invasion of the superior mes-
enteric vein. The patient was started on induction che-
motherapy with FOLFIRINOX (folinic acid, fluorouracil, 
irinotecan, oxaliplatin) in an effort to downsize the tu-
mor. During the first cycle of FOLFIRINOX the patient 
developed swelling of the tongue, slight dyspnea and a 
skin rash 20 min after the start of the irinotecan applica-
tion. The infusion had to be stopped and the symptoms 
slowly resolved after administration of steroids and anti-
histamines. Irinotecan was re-administered 2 weeks later 
causing a similar and more pronounced reaction. The 
treating oncologist was convinced that irinotecan had 
to be discontinued. After contacting our institution he 
agreed to transfer the patient for an attempt to deactiva-
tion. We successfully treated the patient with a third cycle 
of FOLFIRINOX infusing irinotecan in a hyperfraction-
ated manner without any signs of hypersensitivity reac-
tion. After 2 additional cycles of FOLFIRINOX (with 
hyperfractionated irinotecan) a complete resection of the 
pancreatic adenocarcinoma with reconstruction of the su-
perior mesenteric vein could be performed. Postoperative-
ly, FOLFIRINOX with hyperfractionated irinotecan was 
successfully given for another eight cycles again without 
any signs of hypersensitivity.
Hypersensitivity to drugs presents with a wide variety of 
clinical symptoms and can be graded from mild to serve 
(Table 1). Clinical presentation depends on the underly-
ing immunological mechanism. In the 1960s Coombs and 
Gell presented the concept of four mechanisms by which 
substances including drugs can cause hypersensitivity 
reactions. Additional knowledge about the activation of 
T cells has led to the modification of the description of 
the T-cell mediated drug hypersensitivity (Table 2 [4]). 
Type I reactions have a rather typical presentation with 
symptoms of an immediate type reaction arising within 
one hour (rarely several hours) after drug application. The 
manifestation of our clinical case would be considered a 
moderate to severe immediate type reaction. By contrast, 
T-cell mediated late type reactions take place one hour to 
several days after drug administration.
The first challenge in onco-allergology is to identify the 
drug that is most likely responsible for the hypersensitiv-
ity reaction. In the majority of cases chemotherapy regi-
GRADE MILD MODERATE SEVERE
CLINICAL FEATURES
cutaneous and subcutaneous only cardiovascular, respiratory, or 
gastrointestinal  involvement
hypoxia, hypotension or 
neurologic compromise
DEFINING SYMPTOMS 
AND SIGNS
Generalized erythema, periorbital 
edema,  urticarial or angioedema
Dyspnea, stridor, wheeze, nausea, 
vomiting, dizziness, diaphoresis, 
chest or throat tightness, 
abdominal pain
cyanosis or SpO2 ≤92% at any 
stage, hypotension (systolic BP < 
90 mmHg in adults), confusion, 
collapse, loss of consciousness, or 
incontinence
Table 1: Clinical grading of immediate type reactions
   Schweizer Krebsbulletin  Nr. 1/2015 43
ORIGINALARTIKEL
mens consist of multiple drugs given over a few hours, 
often combined with antiemetic drugs.
Therefore, a hypersensitivity reaction to a drug can oc-
cur during the infusion of another drug applied subse-
quently, rendering the identification of the culprit elicitor 
very difficult. The problem is even more difficult in the 
situation of a late type reaction occurring after all drugs 
of a treatment regimen have been applied. To potentially 
identify the responsible drug of an IgE-mediated reaction, 
the method of choice is prick and/or intracutaneous test-
ing. The knowledge on skin testing with anti-neoplastic 
drugs is improving; however, certain substances cannot be 
tested in the skin because of their necrotizing effect or due 
to the fact that non-irritant skin test concentrations have 
not yet been identified and published for many drugs (i.e. 
anthracyclines). In general, the sensitivity of skin testing 
is rather low [4]. At the same time, patients may be in 
urgent need to receive their anti-neoplastic treatment. 
Given the difficulty to perform clinical trials in patients 
with allergic reactions to anti-neoplastic drugs, pragmatic 
decisions have to be made with the aim to allow continu-
ation of an effective poly-chemotherapeutic regimen. In 
addition to the practical need and beside the theoretical 
knowledge about drug hypersensitivity the underlying 
pathophysiologic mechanism of an individual hypersen-
sitivity reaction will remain undefined in most cases. The 
algorithm described below is considered a deactivation 
protocol and not a desensitization protocol since no long 
term tolerance to the cytotoxic agents will be initiated. 
Therefore, every administration of the suspected drug has 
to be done as part of deactivation protocol.
When hypersensitivity to an antineoplastic drug is sus-
pected, we use the following algorithm at our institution: 
First, the patient has to be precisely interviewed about the 
clinical reaction and the patient’s chart has to be critically 
reviewed in order to identify the drug with the highest 
likelihood of being responsible (medical history). Second, 
the oncologist has to evaluate alternative anticancer treat-
ments without the suspected antineoplastic drug. If no 
valid alternative is available and the reaction is clinically 
assumed to represent an immediate-type hypersensitiv-
ity reaction, a desensitization protocol can be considered 
(medical need). If no prompt administration of the next 
cycle of chemotherapy is needed and the knowledge for 
non-irritant and established skin test concentration is 
Type of
immuneresponse
Pathophysiology Clinical symptoms Typical chronology of the 
reaction
I IgE Mast cell and 
basophil 
degranulation
Anaphylactic shock
Angioedema
Urticaria
Bronchospasm
Within 1 to 6 h after the last 
intake of the drug
II IgG and complement IgG and 
complement-dependent
cytotoxicity
Cytopenia 5–15 days after the start of the 
eliciting drug
III IgG or IgM and
complement or FcR
Deposition of 
immune
complexes
Serum sickness
Urticaria
Vasculitis
7–8 days for serum sickness/
urticaria
7–21 days after the start of the 
eliciting drug for vasculitis
IV a Th1 (IFNγ) Monocytic inflammation Eczema 1–21 days after the start of the 
eliciting drug
IV b Th2 (IL-4 and IL-5) Eosinophilic inflammation Maculopapular
exanthema, 
DRESS
1 to several days after the start 
of the eliciting drug for MPE
2–6 weeks after the start of the 
eliciting drug for DRESS
IV c Cytotoxic T cells
(granzyme B, perforin, FasL)
Keratinocyte death
mediated by CD4 or CD8
Maculopapular exanthema,
SJS/TEN, pustular
exanthema
1–2 days after the start of the 
eliciting drug for fixed drug 
eruption
4–28 days after the start of the 
eliciting drug for SJS/TEN
IV d T cells (IL-8/ CXCL8) Neutrophilic inflammation Acute generalized
exanthematous
pustulosis
Typically 1–2 days after the 
start of the eliciting
drug (but could be longer)
Table 2: Classification of drug allergies (published in [4]), maculopapular exanthema (MPE), Stevens-Johnson Syndrome (SJS) 
and Toxic Epidermal Necrolysis (TEN), Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)
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intramuscularly followed by intravenously injected antihis-
tamines [6]. Steroids have no effect in the first minutes of 
the allergic reaction but show a late phase effect.
So far, we have used such hyperfractionated deactivation pro-
tocols for treating patients with mild to severe allergic reac-
tions to the following drugs: rituximab, tocilizumab, irinote-
can, carboplatin and taxanes. We were able to give the drugs 
at therapeutic doses in all patients. Thus, before changing 
the anti-neoplastic drugs to a potentially less effective alter-
native because of hypersensitivity reactions, a hyperfraction-
ated application should be considered, preferably applied at a 
center with experience in deactivation treatments.
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available, prick and intracutaneous testing is performed at 
the Department of Dermatology (Allergy Unit) (testing). 
Ideally, skin testing is performed with various concentra-
tions of the suspected drug to increase the knowledge of 
non-irritant concentrations of cytotoxic agents. Further-
more, plasma tryptase level is measured in all patients 
with immediate type reaction to rule out the possibility of 
an underlying mastocytosis. Specifically, since tryptase is a 
marker of mast cell degranulation during an allergic IgE-
mediated reaction, it should be measured at 1 to 4 hours 
after an adverse infusion reaction has occurred. Measure-
ment of increased serum tryptase concentration supports 
the suspicion that a reaction may be IgE mediated.
Finally, deactivation treatment is performed applying the 
following considerations. For reactions considered to be 
of the immediate type we use a 12-step hyperfractionated 
deactivation protocol [5]. Deactivation treatment is usually 
not performed for cytotoxic drugs causing late type reac-
tions. Importantly, deactivation treatment is contraindicat-
ed , if the patient  had developed severe skin reactions such 
as Stevens-Johnson-Syndrom, Lyell-Syndrom or DRESS 
(Drug Rash with Eosinophilia and Systemic Symptoms).
Patients are treated with anti-histamines and steroids 12 
hours and one hour before the start of the deactivation 
protocol. The protocol is designed to increase the admin-
istered concentration of the anti-neoplastic drug every 15 
min until the final dose is reached within approximately 
6 hours. For the first deactivation treatment the patient is 
admitted to the intensive care unit to insure close moni-
toring of vital signs and immediate medical intervention 
in case of an adverse reaction. For the first hyperfraction-
ated application only a single suspected drug is applied. 
The remaining substances of the poly-chemotherapy regi-
men are administered one day later with the exception 
of antiemetic drugs. When tolerance is good, further ap-
plications are performed in an outpatient setting and the 
remaining drugs of poly-chemotherapy can be given after 
the hyperfractionated drug application on the same day.
In all cases the deactivation protocol has to be closely moni-
tored by a physician to insure prompt intervention in case 
of any hypersensitivity reaction. The treatment of choice 
for a severe hypersensitivity reaction is adrenalin injected 
